Health Canada Gives Medipharm Labs Corp (OTCMKTS: MEDIF) a Nod to Proceed with its CBD50 Product Phase 2 Study

Medipharm Labs Corp (OTCMKTS: MEDIF) applauds Health Canada for giving the nod to  McMaster University to continue researching with MediPharm Labs CBD50 and CBD10:2. The body gave the company’s research partner a no objection letter, giving it the right to engage in its phase 2 trial. 

Seeking a working solution for Insomnia.

MediPharm Labs considers the latest development to be a step towards the right direction in treating Insomnia. The company hopes the study will showcase the safety and efficacy of cannabis oil in helping patients struggling with the condition for many years. A Professor at McMaster University called Dr. Benicio Frey would offer leadership to the clinical research group that will conduct the study. 

Analysts applaud North America for its significant role in eliminating and diagnosing the stigma surrounding mental health. In addition, the study marks a new dawn as more patients move out in search of working treatment options.

The Researchers seem optimistic about how cannabidiol (“CBD”) with or without THC could bring about a new and exciting dynamic in treatment. For example, it could help in offering a working solution for handling sleep disorders linked to depression. 

Strachan speaks out

The researchers will resort to top-quality formulation in conducting the clinical trial. MediPharm Labs vows to stay at the top of its game. It has its Drug Establishment Licence and Cannabis Drug Licence ready, outlining that the licenses will simplify matters. It targets the delivery of clinical trial material that matches Good Manufacturing Practices and pharmaceutical quality standards. 

The Interim CEO of MediPharm Labs, Keith Strachan, opines, “As a pharmaceutical company specialized in cannabis, MediPharm Labs is encouraged by the ongoing research and development of drugs containing cannabis. This study will create opportunities to show efficacy in our already commercialized cannabis oil while also making progress on our long-term goal to manufacture pharmaceutical drugs containing cannabinoids as an active ingredient.”